Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Investor group presses U.S. drug companies on opioid controls

U.S. shareholder activists are addressing a soaring death toll from opioid drug abuse, asking companies that make and distribute the painkillers to review the risks their businesses could face from their role in the sector.

Read More »

Trump’s drug czar nominee withdraws from consideration

President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Read More »

FDA rejects AcelRx Pharma’s opioid painkiller

Shares of AcelRx Pharmaceuticals plunged more than 60 percent after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

Read More »

Cigna to end OxyContin painkiller coverage, signs contract for alternative

Amid a growing U.S. opioid addiction, health insurer Cigna Corp. will stop covering OxyContin – the opioid painkiller sold by Purdue Pharma LP – as of Jan. 1, 2018, and will instead cover an equivalent with a formulation less vulnerable to abuse.

Read More »

FDA declines to approve opioid painkiller

The FDA declined to approve Intellipharmaceutics International ‘s long-acting opioid painkiller in its current form.

Read More »

Drug Enforcement Administration proposes cutting production of some opioid painkillers

The U.S. DEA proposed a 20 percent reduction in the manufacture of certain commonly prescribed opioid painkillers as well as other controlled substances for 2018.

Read More »

Endo International Slashes 875 Jobs and Will Shutter Alabama Facilities

July 21, 2017 By Alex Keown, Breaking News Staff DUBLIN – Less than one month after Endo International (ENDP) agreed to pull its opioid pain medication, the reformulated Opana ER, from the market, the company announced it was shuttering a manufacturing facility in Alabama and terminating hundreds of employees. Endo said the move follows […]

Read More »

Anthem files lawsuit against Insys Therapeutics

Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

Read More »

U.S. to crack down on opioid treatment programs: Bloomberg

U.S. Attorney General Jeff Sessions will unveil a major crackdown on healthcare fraud involving opioid treatment programs, Bloomberg News reported, citing two people familiar with the matter.

Read More »

Mallinckrodt settles U.S. opioid drug probe for $35 million

Mallinckrodt Plc, one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom